



## Latest Advances in Molecular and Cellular Immunotherapy

Guest Editors:

### Dr. Bruno Cadilha

Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany

### Dr. Mohamed-Reda Benmebarek

Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Deadline for manuscript submissions:  
**closed (30 November 2022)**

### Message from the Guest Editors

Dear Colleagues,

The immune system's role in infection and cancer therapy has been on the spotlight of medical breakthrough for the past decade. The advent of immune checkpoint blockade therapy, the success of genetic engineered T cells in hematological malignancies or the record-breaking development and approval of COVID-19 vaccines are true feats of modern medicine. The dust from these aforementioned technological breakthroughs as yet to settle. We are striding towards completion of key trials that combine immunotherapy with other well-established treatment modalities. New mechanisms of action of these recently approved therapies keep being unveiled. Molecular fine-tuning, production scalability and the socio-economical impact of these new therapeutics are far from reaching maturity.

We look forward to receiving your contributions.

Dr. Bruno Loureiro Cadilha  
Dr. Mohamed-Reda Benmebarek  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)